[
  {
    "ts": null,
    "headline": "Chai Discovery Announces $70 million Series A To Transform Molecular Design",
    "summary": "SAN FRANCISCO, August 06, 2025--Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules to accelerate life-changing therapeutics, today announced its $70 million Series A financing round.",
    "url": "https://finnhub.io/api/news?id=3949aea2e1c4d514e9fd11aa2566e4275e1c0417bd972ca957b5538b9b702c47",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754503500,
      "headline": "Chai Discovery Announces $70 million Series A To Transform Molecular Design",
      "id": 136240903,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, August 06, 2025--Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules to accelerate life-changing therapeutics, today announced its $70 million Series A financing round.",
      "url": "https://finnhub.io/api/news?id=3949aea2e1c4d514e9fd11aa2566e4275e1c0417bd972ca957b5538b9b702c47"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Q2: Dividends Speak Louder Than EPS",
    "summary": "At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate PFE stock a Sell.",
    "url": "https://finnhub.io/api/news?id=7f6f938231eee2b025b3a1245fcb7e0f2a0633aeb2f092ca1f80fa00383f0fc3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754502164,
      "headline": "Pfizer Q2: Dividends Speak Louder Than EPS",
      "id": 136242133,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate PFE stock a Sell.",
      "url": "https://finnhub.io/api/news?id=7f6f938231eee2b025b3a1245fcb7e0f2a0633aeb2f092ca1f80fa00383f0fc3"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment.",
    "summary": "RFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment.",
    "url": "https://finnhub.io/api/news?id=a07cde59a28ecf96ff2648c948f0086e1fc63cd06780194bd984debeec7af54b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754494020,
      "headline": "RFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment.",
      "id": 136252133,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "RFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment.",
      "url": "https://finnhub.io/api/news?id=a07cde59a28ecf96ff2648c948f0086e1fc63cd06780194bd984debeec7af54b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer CEO says has spoken with Trump, in ‘productive’ talks with government",
    "summary": "On the company’s Q2 earning call, Pfizer (PFE) noted that the company’s guidance “absorbs the impact of the currently imposed tariffs from China, Canada and Mexico as well as potential price changes this year based on the letter received on July 31 from President Trump.” Later in the call, Pfizer CEO Albert Bourla said the company is “in very active discussions” at “the highest levels of this government.” Bourla added: “I discussed myself with the president after he sent the letter to me and all",
    "url": "https://finnhub.io/api/news?id=15b27f8be9cdee07f1201d2a66fe597c803cb469e98d06d061807b32730ac880",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754491525,
      "headline": "Pfizer CEO says has spoken with Trump, in ‘productive’ talks with government",
      "id": 136237339,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On the company’s Q2 earning call, Pfizer (PFE) noted that the company’s guidance “absorbs the impact of the currently imposed tariffs from China, Canada and Mexico as well as potential price changes this year based on the letter received on July 31 from President Trump.” Later in the call, Pfizer CEO Albert Bourla said the company is “in very active discussions” at “the highest levels of this government.” Bourla added: “I discussed myself with the president after he sent the letter to me and all",
      "url": "https://finnhub.io/api/news?id=15b27f8be9cdee07f1201d2a66fe597c803cb469e98d06d061807b32730ac880"
    }
  },
  {
    "ts": null,
    "headline": "Moderna’s stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals",
    "summary": "Moderna’s stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals",
    "url": "https://finnhub.io/api/news?id=172946174033ef2b96e42b9534e548891ec5931780da9988fd9689f72043f1e7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754489940,
      "headline": "Moderna’s stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals",
      "id": 136252134,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Moderna’s stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals",
      "url": "https://finnhub.io/api/news?id=172946174033ef2b96e42b9534e548891ec5931780da9988fd9689f72043f1e7"
    }
  },
  {
    "ts": null,
    "headline": "Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=4f3a4c744d7d840e27ca592b28942369d8e6c776772a471498811a2b5f23c37c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754487903,
      "headline": "Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term",
      "id": 136239149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=4f3a4c744d7d840e27ca592b28942369d8e6c776772a471498811a2b5f23c37c"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Aug 6, 2025",
    "summary": "Companies in The News Are: PFE,MPC,CMI,GLDD",
    "url": "https://finnhub.io/api/news?id=4e47a65dd7f12cd5e851fc597161ea56befc0a92285c37becd931feb0f1007b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754486880,
      "headline": "Company News for Aug 6, 2025",
      "id": 136237340,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Companies in The News Are: PFE,MPC,CMI,GLDD",
      "url": "https://finnhub.io/api/news?id=4e47a65dd7f12cd5e851fc597161ea56befc0a92285c37becd931feb0f1007b6"
    }
  },
  {
    "ts": null,
    "headline": "BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?",
    "summary": "BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.",
    "url": "https://finnhub.io/api/news?id=3f3c0427ee8360691a66d41e168fa554ace4c2c8aa1e153e9298eec25c004256",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754486280,
      "headline": "BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?",
      "id": 136237341,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.",
      "url": "https://finnhub.io/api/news?id=3f3c0427ee8360691a66d41e168fa554ace4c2c8aa1e153e9298eec25c004256"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Second Quarter 2025 Earnings: Beats Expectations",
    "summary": "Pfizer ( NYSE:PFE ) Second Quarter 2025 Results Key Financial Results Revenue: US$14.7b (up 10% from 2Q 2024). Net...",
    "url": "https://finnhub.io/api/news?id=b568f88be98b7cfabd8474ab247cde2001ac275311ef45c4210e3ed0e9c80a55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754480246,
      "headline": "Pfizer Second Quarter 2025 Earnings: Beats Expectations",
      "id": 136237342,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer ( NYSE:PFE ) Second Quarter 2025 Results Key Financial Results Revenue: US$14.7b (up 10% from 2Q 2024). Net...",
      "url": "https://finnhub.io/api/news?id=b568f88be98b7cfabd8474ab247cde2001ac275311ef45c4210e3ed0e9c80a55"
    }
  },
  {
    "ts": null,
    "headline": "Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share",
    "summary": "The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled sales numbers for their chief drugs.",
    "url": "https://finnhub.io/api/news?id=81dd0d826d6f6812e60b3ec1bcfc074c25af74a0a930194d420e3897b3f20dc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754479800,
      "headline": "Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share",
      "id": 136239150,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled sales numbers for their chief drugs.",
      "url": "https://finnhub.io/api/news?id=81dd0d826d6f6812e60b3ec1bcfc074c25af74a0a930194d420e3897b3f20dc5"
    }
  },
  {
    "ts": null,
    "headline": "1 Reason to Buy Pfizer (PFE) Stock",
    "summary": "How does $740 in annual income sound?",
    "url": "https://finnhub.io/api/news?id=b729a29cadc5dd856c690e4cf2c0041d0c38a93a2b3bf6dd793411689b6e252f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754478900,
      "headline": "1 Reason to Buy Pfizer (PFE) Stock",
      "id": 136232387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "How does $740 in annual income sound?",
      "url": "https://finnhub.io/api/news?id=b729a29cadc5dd856c690e4cf2c0041d0c38a93a2b3bf6dd793411689b6e252f"
    }
  },
  {
    "ts": null,
    "headline": "US Health Department Ending Federal mRNA Vaccine Development",
    "summary": "The US Health and Human Services Department said Tuesday it will soon end federal mRNA vaccine proje",
    "url": "https://finnhub.io/api/news?id=294cfc2940509d17e0297bab8434380ebca59456f5886d62a0a1aa2d4679fa4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754476236,
      "headline": "US Health Department Ending Federal mRNA Vaccine Development",
      "id": 136232388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The US Health and Human Services Department said Tuesday it will soon end federal mRNA vaccine proje",
      "url": "https://finnhub.io/api/news?id=294cfc2940509d17e0297bab8434380ebca59456f5886d62a0a1aa2d4679fa4d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Pops Despite Looming Pharma Tariffs",
    "summary": "The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US patients.",
    "url": "https://finnhub.io/api/news?id=9269745b3bba3f670affceaba93a9c88b7bbfb079cfd62c8fa83adf69b6aa039",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754476200,
      "headline": "Pfizer Pops Despite Looming Pharma Tariffs",
      "id": 136238280,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US patients.",
      "url": "https://finnhub.io/api/news?id=9269745b3bba3f670affceaba93a9c88b7bbfb079cfd62c8fa83adf69b6aa039"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Have Been Beaten Up. The Case for Buying Now.",
    "summary": "Healthcare stocks have been the sick man of the  this year.  The  exchange-traded fund has fallen 3.7% this year, far worse than the S&P 500’s 7.1% rise.  The ETF includes everything from insurers to pharma companies to medical-device makers, and that diversity usually helps the group weather the tough times.",
    "url": "https://finnhub.io/api/news?id=9a8e4064a99bde35e95e225106c6771e3156aa6b8dc50846fccc1e9bb0a4e06f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754469000,
      "headline": "Healthcare Stocks Have Been Beaten Up. The Case for Buying Now.",
      "id": 136232196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Healthcare stocks have been the sick man of the  this year.  The  exchange-traded fund has fallen 3.7% this year, far worse than the S&P 500’s 7.1% rise.  The ETF includes everything from insurers to pharma companies to medical-device makers, and that diversity usually helps the group weather the tough times.",
      "url": "https://finnhub.io/api/news?id=9a8e4064a99bde35e95e225106c6771e3156aa6b8dc50846fccc1e9bb0a4e06f"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Antibody Drug Conjugates Market Research 2025-2031 | Pfizer, AstraZeneca, and Biotechs Like Miracogen Advance Cancer ADCs with Strategic Acquisitions and Innovative Pipelines",
    "summary": "Global Cancer Antibody Drug Conjugates Market poised to exceed USD 70 billion by 2031, driven by over 20 approved drugs. Report offers insights into market size, sales, pricing, and clinical trials with over 800 ADC candidates. Explore key R&D collaborations and future growth trends in targeted cancer therapy.Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The \"Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2031\" report has been added t",
    "url": "https://finnhub.io/api/news?id=91649a458388fbea93b6f363e1c0ddb5e37f22a62a618bf64a6059171d2f23fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754468520,
      "headline": "Cancer Antibody Drug Conjugates Market Research 2025-2031 | Pfizer, AstraZeneca, and Biotechs Like Miracogen Advance Cancer ADCs with Strategic Acquisitions and Innovative Pipelines",
      "id": 136232390,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Global Cancer Antibody Drug Conjugates Market poised to exceed USD 70 billion by 2031, driven by over 20 approved drugs. Report offers insights into market size, sales, pricing, and clinical trials with over 800 ADC candidates. Explore key R&D collaborations and future growth trends in targeted cancer therapy.Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The \"Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2031\" report has been added t",
      "url": "https://finnhub.io/api/news?id=91649a458388fbea93b6f363e1c0ddb5e37f22a62a618bf64a6059171d2f23fc"
    }
  }
]